| Ol (lots) | Call Price | Strike Price | Put Price | Ol (lots) |
|---|---|---|---|---|
| - | - | 4,800 | ₹3.05 0% | 4,2500% |
| - | - | 4,900 | ₹0.05 0% | 1250% |
| 1250% | ₹720 0% | 5,000 | ₹4.1 0% | 3750% |
| - | - | 5,050 | ₹3.25 0% | 3750% |
| - | - | 5,100 | ₹3.7 0% | 1,7500% |
| - | - | 5,200 | ₹2.5 -45.05% | 8,3750% |
| 1250% | ₹472.75 0% | 5,300 | ₹5.15 -26.42% | 11,12541.26% |
| - | - | 5,400 | ₹10.75 -12.24% | 7,750-3.12% |
| 1250% | ₹209.3 0% | 5,450 | ₹14.95 -40.2% | 16,3754.8% |
| 5000% | ₹214.4 6.21% | 5,500 | ₹20.8 -32.02% | 24,000-2.53% |
| - | - | 5,550 | ₹32.4 -25.6% | 7,62519.60% |
| 10,375-20.95% | ₹119.2 27.69% | 5,600 | ₹39.95 -30.34% | 17,25016.94% |
| 11,6255.68% | ₹86.3 32.36% | 5,650 | ₹57 -32.02% | 10,87533.84% |
| 31,500-10.63% | ₹61.5 31.27% | 5,700 | ₹82.05 -42.42% | 15,375-4.65% |
| 17,625-0.70% | ₹34.4 -12.8% | 5,750 | ₹172 0% | 10,6250% |
| 38,8754.71% | ₹26.65 22.52% | 5,800 | ₹150.75 0% | 16,6250% |
| 7,8750% | ₹20.8 0% | 5,850 | ₹211.6 0% | 1,1250% |
| 38,375-0.32% | ₹12 25% | 5,900 | ₹224.45 0% | 2500% |
| 33,375-8.24% | ₹6.35 30.92% | 6,000 | ₹350.75 0% | 2500% |
| 9,125-1.35% | ₹3.4 51.11% | 6,100 | - | - |
| 4,0000% | ₹3.5 75% | 6,200 | ₹494.7 0% | 1250% |
| 6250% | ₹9.85 369.04% | 6,250 | - | - |
| 1,2500% | ₹2 0% | 6,300 | - | - |
| 2500% | ₹2.65 0% | 6,400 | - | - |
| 1,5000% | ₹17.65 0% | 6,500 | - | - |
This inspection, conducted from March 10 through March 13, 2025, was to evaluate compliance with the legal standards concerning bioequivalence studies.
The company saw its revenues increase by 1.5% YoY at ₹3,374 crore from ₹3,324 crore.
The serum contains liposomal azelaic acid, liposomal 4-butyl resorcinol, tranexamic acid, alpha arbutin, and niacinamide.
R&D expenses rose to ₹146.5 crore, making up 4.3% of total revenue, compared to ₹115.8 crore (3.4% of revenue) in the previous year.
This comes after competing private equity firms TPG Capital, Apax Partners, and KKR withdrew their original interest.
Alkem will conduct clinical trials of 'SON-080' in India, with Sonnet's support for global and local regulatory submissions.
According to sources, the floor price would be ₹5,616 per share, which is 3% lower than the current market price (CMP).
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor), PFRDA Reg. No. PoP 20092018
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
